NCT00789555

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,260 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).

Conditions

• Perennial Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Olopatadine hydrochloride 0.6% nasal spray (PATANASE)	Two sprays in each nostril twice a day (morning and evening) for up to 12 months
OTHER	Olopatadine nasal spray vehicle, pH 3.7	Two sprays in each nostril twice a day (morning and evening) for up to 12 months
OTHER	Olopatadine nasal spray vehicle, pH 7.0	Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Timeline

• Start date: 2008-11-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2008-11-13
• Last updated: 2018-02-08
• Results posted: 2012-09-07

Locations

1 site across 1 country: United States